Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
RNAC on Nasdaq
Shares outstanding
25,973,289
Price per share
$7.22
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
5,968,086
Total reported value
$60,898,831
% of total 13F portfolios
0%
Share change
-433,710
Value change
-$4,440,064
Number of holders
65
Price from insider filings
$7.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SPRINGER TIMOTHY A 37% +0.27% $116,671,361 +$258,583 9,555,394 +0.22% Timothy A. Springer 13 Jan 2025
FMR LLC 8.3% -12% $22,041,372 -$2,734,285 2,155,783 -11% FMR LLC 30 Sep 2025
JPMORGAN CHASE & CO 6.1% $20,459,516 1,675,636 JPMORGAN CHASE & CO. 31 Mar 2025

As of 30 Sep 2025, 65 institutional investors reported holding 5,968,086 shares of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC). This represents 23% of the company’s total 25,973,289 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) together control 22% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 8.3% 2,155,783 -7.6% 0% $22,032,103
BlackRock, Inc. 2.5% 649,341 -0.69% 0% $6,636,266
Siren, L.L.C. 2.2% 563,272 0% 0.23% $5,756,640
VANGUARD GROUP INC 2% 520,722 +4.9% 0% $5,321,779
MPM BIOIMPACT LLC 1.5% 380,000 -45% 0.64% $3,883,600
Erste Asset Management GmbH 1% 260,011 0% 0.02% $2,561,108
GEODE CAPITAL MANAGEMENT, LLC 0.93% 241,829 +10% 0% $2,471,880
683 Capital Management, LLC 0.89% 230,000 +5% 0.21% $2,350,601
STATE STREET CORP 0.76% 197,666 +1.7% 0% $2,020,147
NORTHERN TRUST CORP 0.35% 91,289 +10% 0% $932,974
GSA CAPITAL PARTNERS LLP 0.33% 86,095 +107% 0.07% $880,000
MARSHALL WACE, LLP 0.33% 84,806 +2.6% 0% $866,718
CITADEL ADVISORS LLC 0.27% 70,524 -42% 0% $720,756
ROYAL BANK OF CANADA 0.14% 36,222 +98% 0% $370,000
JACOBS LEVY EQUITY MANAGEMENT, INC 0.12% 30,001 -27% 0% $306,610
Freestone Capital Holdings, LLC 0.1% 25,921 0% 0.01% $264,913
MILLENNIUM MANAGEMENT LLC 0.1% 25,357 0% $259,149
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% 25,000 0.01% $255,500
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.1% 24,895 -0.03% 0% $254,427
Nuveen, LLC 0.09% 24,497 0% 0% $250,359
Bank of New York Mellon Corp 0.09% 24,191 -3.2% 0% $247,231
Ikarian Capital, LLC 0.09% 22,166 0% 0.05% $226,537
TWIN FOCUS CAPITAL PARTNERS, LLC 0.08% 19,500 +2.6% 0.03% $199,290
MORGAN STANLEY 0.07% 18,974 -35% 0% $193,914
BARCLAYS PLC 0.07% 17,842 -42% 0% $182,346

Institutional Holders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$1,758 $7.22 0
2025 Q3 5,968,086 $60,898,831 -$4,440,064 $10.22 65
2025 Q2 6,401,037 $66,468,780 -$2,049,017 $10.39 65
2025 Q1 6,582,077 $86,710,172 -$755,346 $13.18 68
2024 Q4 6,665,799 $119,478,509 -$2,692,613 $17.91 64
2024 Q3 6,867,968 $110,349,366 +$42,879,892 $16.12 61
2024 Q2 3,268,033 $88,276,427 +$88,059,260 $27.01 57
2024 Q1 1,855 $1,157 +$1,157 $0.64 4
2023 Q4 0 $0 -$1,272 $7.22 0
2023 Q3 1,200 $1,272 $1.06 1
2023 Q2 1,200 $1,344 $1.12 1
2023 Q1 1,200 $1,668 +$1,668 $1.39 1